Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Completed · Phase 1
Conditions studied: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
In brief
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pemetrexed together with cisplatin and paclitaxel and giving them in different ways may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of intraperitoneal pemetrexed when given together with intraperitoneal cisplatin and paclitaxel in treating patients with stage III ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.
Key facts
- Study ID
- NCT00702299
- Run by
- University of Arizona
- People needed
- 15
- Starts
- 2007-09-01
- Expected to finish
- 2012-10-01
- Last updated by the study team
- 2016-01-01
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Arizona Oncology - Scottsdale — Scottsdale, Arizona, United States
- Arizona Cancer Center at University of Arizona Health Sciences Center — Tucson, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.